Sandra Casinghino, MS

Noticing indicators of IVIG non-responsiveness can lead to better outcomes among patients with Kawasaki disease as treatment is adjusted.

Study participants’ overall satisfaction with a mandatory nationwide adalimumab transition in New Zealand varied but was generally low.

In the study, a new policy empowered unit-based pharmacists to evaluate the patient’s needs and, when safe, switch from a PPI to an H2 blocker.